Search

Amiodarone for Repurfusion Arrhythmia after Thrombolytic Therapy for Acute Myocardial Infarction: A Meta-Analysis

Objective　To systematically review the effectiveness of amiodarone in treating repurfusion arrhythmia (RA) after thrombolytic therapy for acute myocardial infarction (AMI), so as to provide high quality evidence for formulating the rational thrombolytic therapy for AMI. Methods　Randomized controlled trails (RCTs) on amiodarone in treating RA after thrombolytic therapy for AMI were electronically retrieved in PubMed, EMbase, The Cochrane Library (Issue 3, 2012), CBM, CNKI, VIP and WanFang Data from inception to January, 2013. According to the inclusion and exclusion criteria, two reviewers independently screened literature, extracted data, and assessed quality. Then RevMan 5.1 software was used for meta-analysis. Results　A total of 5 RCTs involving 440 patients were included. The results of meta-analysis suggested that, compared with the blank control, amiodarone reduced the incidence of RA after thrombolytic therapy in treating AMI (RR=0.60, 95%CI 0.48 to 0.74, Plt;0.000 01) and the incidence of ventricular fibrillation (RR=0.47, 95%CI 0.26 to 0.85, P=0.01). It neither affected the recanalization rate of occluded arteries after thrombolytic therapy (RR=1.00, 95%CI 0.88 to 1.15, P=0.94) nor decreased the mortality after surgery (RR=0.33, 95%CI 0.10 to 1.09, P=0.07). Conclusion　Current evidence indicated that, amiodarone can decrease the incidence of RA. Unfortunately, the mortality rate can’t be reduced by amiodarone. Due to the limited quality and quantity of the included studies, more high quality studies are needed to verify the above conclusion

The Cochrane systematic review of iodised salt for preventing iodine deficiency disorders

Backgroud　Iodine deficiency is the main cause for potentially preventable mental retardation in childhood and is still prevalent in large parts of the world. Objectives　To assess the effects of iodised salt in comparison with other forms of iodine supplementation or placebo in the prevention of iodine deficiency disorders.Search strategy　We searched the Cochrane Library, Medline, the Register of Chinese trials developed by the Chinese Cochrane Centre, and the Chinese Med Database. We performed handsearching of a number of journals (Chinese Journal of Control of Endemic Diseases, Chinese Journal of Epidemiology, Chinese Journal of Preventive Medicine, and Studies of Trace Elements and Health up to February 2001), and searched reference lists, databases of ongoing trials and the Internet. Date of latest search: November 2001. Selection Criteria　We included prospective controlled studies of iodised salt versus other forms of iodine supplementation or placebo in people living in areas of iodine deficiency. Studies reported mainly goitre rates and urinary iodine excretion as outcome measures. Data collection amp; analysis　As the studies identified were not sufficiently similar and not of sufficient quality, we did not do a meta-analysis but summarised the data in a narrative format. Main results　We found six prospective controlled trials relating to our question. Four of these were described as randomised controlled trials, one was a prospective trial that did not specify allocation to comparison groups, and one was a large population-based study comparing different interventions. Comparison interventions included non-iodised salt, iodised water, iodised oil, iodation with potassium iodide versus potassium iodate. Numbers of participants in the trials ranged from 35 to 334; over 20 000 people were included in the population-based study. There was a tendency towards goitre reduction with iodised salt, although this was not significant in all studies. There was aim an improved iodine status in most studies (except in small children in one of the studies), although urinary iodine excretion did not always reach the levels recommended by the WHO. Reviewers’ conclusions　The results suggest that iodised salt is an effective and safe means of improving iodine status. However, high quality controlled studies are needed to address questions of dosage and best means of iodine supplementation in different population groups.

Change of Serum TRAb Level in Patients with Graves’ Ophthalmopathy before and after Treated with 131I

目的　探讨碘131（131I）治疗后Graves眼病（GO）预后与血清促甲状腺激素受体抗体（TRAb）水平变化之间的关系。 方法　选择2011年5月－12月初发Graves病患者238例，分为GO组124 例和非GO组114 例，分别检测131I治疗前及131I治疗后2、3、6个月甲状腺功能和TRAb，GO患者131I治疗前和治疗后6 个月进行临床活动度评分（CAS）。 结果　131I治疗前各组TRAb水平差异无统计学意义（P＞0.05），TRAb水平与GO CAS评分之间无相关；131I治疗后6个月所有患者TRAb水平显著增加；非GO组有5例新发GO，新发GO组与其他患者的TRAb水平分别为（58.7 ± 77.9）、（61.9 ± 81.1）U/L，差异无统计学意义（P＞0.05）；GO组又分为GO无变化29例，GO加重17例，GO缓解78例，三组患者TRAb水平分别为（53.5 ± 77.6）、（66.2 ± 89.9）、（66.8 ± 42.2）U/L，差异无统计学意义（P＞0.05）。 结论　131I治疗后患者TRAb水平显著增加，但TRAb水平的变化和GO预后无关，TRAb与GO的关系还需要进一步研究。

不同消毒液对头孢美唑钠皮试阳性结果的影响

【摘要】　目的　提高对头孢美唑钠皮试阳性结果判断的准确性，更加安全有效的使用抗生素。　方法　选择2009年8月-2011年1月对接受痔瘘手术的患者1 000例，分为组间对照组（n=500）和自身对照组（n=500）观察安尔碘和75%乙醇两种皮肤消毒液作头孢美唑钠皮试后出现的假阳性率。　结果　组间对照组及自身对照组头孢美唑钠皮试假阳性率，安尔碘为 1.6%和1.2%，75%乙醇为10.8%和9.0%。　结论　与75%乙醇比较，安尔碘能降低头孢美唑钠的假阳性率，提高使用抗生素的安全性。

放射性131碘治疗甲亢合并周期性麻痹36例临床结果分析

目的:探讨甲亢合并周期性麻痹(TPP)的发病情况、临床特点及131碘治疗后的疗效分析。方法:回顾性分析36例甲亢合并TPP患者与43例甲亢不伴TPP患者的临床资料及131碘治疗后疗效。结果:甲亢合并TPP患者男性明显多于女性,其中尤以30~40岁的青壮年多见;甲亢合并TPP患者平均131碘治疗剂量明显低于对照组(Plt;0.01);经131碘治疗后,甲亢合并TPP患者与对照组在甲亢治愈率、甲减发生率上无显著性差异(Pgt;0.05)。结论:甲亢合并TPP发病男性明显多于女性,与Graves病有明显区别。早期、正确诊断甲亢合并TPP,可避免延误对以周瘫为主要症状的甲亢患者诊治。131碘治疗是一种非常有效的治疗甲亢合并TPP的方法。

Amiodarone for Atrial Fibrillation

目的:研究胺碘酮治疗心房颤动的疗效。方法:用胺碘酮治疗心房颤动患者68例(阵发性心房颤动40例,持续性心房颤动28例)。结果:连续用药治疗6个月显示治疗有效率分别为925%、75%。治疗12个月有效率分别为853%、68%。结论:胺碘酮治疗心房颤动安全有效,副作用小,可作为首选药。

The Change of Spectrum of Thyroid Diseases Within Ten Years Implementation of Universal Salt Iodization in Guangxi Zhuang Autonomous Region

Objective　To reveal the relationship between the iodine nutrition and the change of spectrum of thyroiddiseases by analyzing the change of spectrum of thyroid diseases in different iodine environments before and after the implementation of universal salt iodization （USI）. Methods　To compare the urinary iodine concentration between the normal people （1 000 cases） and the patients with thyroid diseases （5 998 cases） by surgical operations who were from 4 cities of Guangxi Zhuang Autonomous Region， covering the iodine deficient areas and the iodine rich areas. Results　After the USI was put into practice， the proportions of nodular goiter decreased， but the proportions of toxic nodular goiter， thyroid papillary carcinoma， and Hashimoto thyroiditis were higher than those before USI （P＜0.05）. The urinaryiodine concentrations of nodular goiter， Graves disease， toxic nodular goiter， thyroid papillary carcinoma， and Hashimotothyroiditis were higher than those before the measure was taken （P＜0.05）. The urinary iodine concentration of patients with thyroid was higher than that of normal people （P＜0.05）， and the urinary iodine concentration of patients with thyroidand normal people was higher than those before the USI （P＜0.05）. Conclusions　The change of spectrum of thyroid diseases in Guangxi Zhuang Autonomous Region is obvious within 10 years after USI had been taken. The excessive intake of iodine may be one of the dangerous factors leading to toxic nodular goiter， thyroid papillary carcinoma， and Hashimoto thyroiditis.

Studies on Induction of Experimental Autoimmune Thyroiditis with Excessive Iodine and Thyroglobulin in Rats

【Abstract】Objective To study the relation between iodine and experimental autoimmune thyroiditis(EAT). Methods Establishment of animal model was performed with iodine and thyroglobulin(TG).The rats were randomly divided into 5 groups: normal control group(NC), low iodine group (LI,500 μg/L), high iodine group(HI,500 mg/L), TG+Freund adjuvant group(TG) and TG+Freund adjuvant+HI group(TG+HI). The rats in TG group and TG+HI group were rejected hypodermically with TG emulsified by complete Freund adjuvant, and strengthen immunity was conducted with TG emulsified by incomplete Freund adjuvant on 15 days. After that, strengthen immunity was done weekly till the end of the experiment. Serum TGAb and TPOAb were measured by radioimmunoassay. Observation of the pathological changes of thyroid gland was also done. Results Thyroid follicular destruction and lymphocytic infiltration in the TG+HI group (3.83±1.72) and HI group (3.00±0.89) were significantly higher than that of the NC group(0.67±0.82)，P＜0.05. The results of the TG group were higher compared with the NC group, but there were no significant differences between them（Pgt;0.05）. The levels of TGAb in the TG+HI (4.990±1.505)，HI (3.589±1.240) and TG group (4.883±1.198) were significant higher than those of the NC group (0.642±0.454) and the LI group (0.707±0.240)，P＜0.01. The levels of TPOAb in TG+HI group (1.475±0.523) and TG group (1.316±0.606) were significantly higher than those of the NC group (0.365±0.196) and the LI group（P＜0.01）. Serum TGAb and TPOAb levels were positively correlated with the histological grades of lymphocytic thyroiditis(r=0.9,P＜0.05）. Conclusion Excessive iodine intake may induce the occurrence of EAT. The induction of EAT with excessive iodine and TG may be more efficient.

胃癌及胃溃疡患者血清T３测定的临床意义

ANEXPERIMENTAL STUDY OF 131I—LIPIODOL HEPATIC ARTERIAL EMBOLIZATION.

１３１Ｉ was labeled on lipiodol molecule by an iodine exchange reaction. The labeling rate was 95%. No dehalogenation was detected within 15 days at room temperature or after slerilization. Animal experiments showed that after hepatic arteial injection, １３１Ｉ-lipiodol was selectively accumulated in the embolizated local area. No increased acti-vity was observed in thyroid, lung or other areas in the body. The blood radioactivity per ml was 0.09±0.04% of the injectd dose. The result suggest that １３１Ｉ-lipiodol is very stable and suitable for clinical application.